F B N Simo1, J J Bigna2, E A Well3, S Kenmoe4, F B Y Sado5, S C Weaver6, P F Moundipa7, M Demanou8. 1. Department of Virology, Reference Laboratory for Chikungunya and Dengue Viruses, Centre Pasteur of Cameroon, Member of the International Network of Pasteur Institutes, 451 Rue 2005, P.O. Box 1274, Yaoundé, Cameroon; Department of Biochemistry, Faculty of Sciences, University of Yaoundé I, P.O. Box 337, Yaoundé, Cameroon. Electronic address: nemgsi@yahoo.fr. 2. Department of Epidemiology and Public Health, Centre Pasteur of Cameroon, Member of the International Network of Pasteur Institutes, 451 Street 2005, P.O. Box 1274, Yaoundé, Cameroon; School of Public Health, Faculty of Medicine, University of Paris Sud, 63 Rue Gabriel Péri, 94270, Le Kremlin-Bicêtre, France. Electronic address: bignarimjj@yahoo.fr. 3. Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, P.O. Box 1364, Yaoundé, Cameroon. Electronic address: estelleamandinewell@yahoo.fr. 4. Department of Virology, Reference Laboratory for Chikungunya and Dengue Viruses, Centre Pasteur of Cameroon, Member of the International Network of Pasteur Institutes, 451 Rue 2005, P.O. Box 1274, Yaoundé, Cameroon. Electronic address: ken_sebas@yahoo.fr. 5. Department of Virology, Reference Laboratory for Chikungunya and Dengue Viruses, Centre Pasteur of Cameroon, Member of the International Network of Pasteur Institutes, 451 Rue 2005, P.O. Box 1274, Yaoundé, Cameroon. Electronic address: francine.sado@yahoo.com. 6. Institute for Human Infections and Immunity and Department of Microbiology and Immunology, University of Texas Medical Branch, 301 University Blvd, Galveston, TX, 77555, USA. Electronic address: sweaver@utmb.edu. 7. Department of Biochemistry, Faculty of Sciences, University of Yaoundé I, P.O. Box 337, Yaoundé, Cameroon. Electronic address: pmoundipa@hotmail.com. 8. Department of Virology, Reference Laboratory for Chikungunya and Dengue Viruses, Centre Pasteur of Cameroon, Member of the International Network of Pasteur Institutes, 451 Rue 2005, P.O. Box 1274, Yaoundé, Cameroon. Electronic address: demanou@pasteur-yaounde.org.
Abstract
OBJECTIVES: The (re)emergence of chikungunya virus (CHIKV) in Africa requires better knowledge on the epidemiology of CHIKV infection in the continent for efficient public health strategies. We aimed to describe the epidemiology of CHIKV infection in Africa, a neglected tropical disease (NTD). STUDY DESIGN: This was a systematic review with meta-analysis of studies reporting CHIKV infection prevalence. We searched Embase, PubMed, Africa Journal Online and Global Index Medicus to identify observational studies published from January 2000 to September 2017. METHODS: We used a random-effect model to pool the prevalence of CHIKV infections reported with their 95% confidence interval (CI). Heterogeneity was assessed via the Chi-squared test on Cochran's Q statistic. Review registration is in PROSPERO CRD42017080395. RESULTS: A total of 39 studies (37,881 participants; 18 countries) were included. No study was reported from Southern Africa. Thirty-two (82.0%), seven (18.0%) and no studies had low, moderate and high risk of bias, respectively. Outside outbreak periods, the pooled immunoglobulin M (IgM) and immunoglobulin G (IgG) seroprevalence was 9.7% (95% CI 3.0-19.6; 16 studies) and 16.4% (95% CI 9.1-25.2; 23 studies), respectively. The IgM seroprevalence was lower in Northern Africa, and there was no difference for IgG prevalence across regions in Africa. The IgM and IgG seroprevalences were not different between acute and non-acute febrile participants. The seroprevalence was not associated with GPS coordinates (latitude, longitude and altitude). CONCLUSIONS: Although considered a NTD, we find high prevalence of CHIKV infection in Africa. As such, chikungunya fever should deserve more attention from healthcare providers, researchers, policymakers and stakeholders from many sectors.
OBJECTIVES: The (re)emergence of chikungunya virus (CHIKV) in Africa requires better knowledge on the epidemiology of CHIKV infection in the continent for efficient public health strategies. We aimed to describe the epidemiology of CHIKV infection in Africa, a neglected tropical disease (NTD). STUDY DESIGN: This was a systematic review with meta-analysis of studies reporting CHIKV infection prevalence. We searched Embase, PubMed, Africa Journal Online and Global Index Medicus to identify observational studies published from January 2000 to September 2017. METHODS: We used a random-effect model to pool the prevalence of CHIKV infections reported with their 95% confidence interval (CI). Heterogeneity was assessed via the Chi-squared test on Cochran's Q statistic. Review registration is in PROSPERO CRD42017080395. RESULTS: A total of 39 studies (37,881 participants; 18 countries) were included. No study was reported from Southern Africa. Thirty-two (82.0%), seven (18.0%) and no studies had low, moderate and high risk of bias, respectively. Outside outbreak periods, the pooled immunoglobulin M (IgM) and immunoglobulin G (IgG) seroprevalence was 9.7% (95% CI 3.0-19.6; 16 studies) and 16.4% (95% CI 9.1-25.2; 23 studies), respectively. The IgM seroprevalence was lower in Northern Africa, and there was no difference for IgG prevalence across regions in Africa. The IgM and IgG seroprevalences were not different between acute and non-acute febrile participants. The seroprevalence was not associated with GPS coordinates (latitude, longitude and altitude). CONCLUSIONS: Although considered a NTD, we find high prevalence of CHIKV infection in Africa. As such, chikungunya fever should deserve more attention from healthcare providers, researchers, policymakers and stakeholders from many sectors.
Authors: Marie Paul Audrey Mayi; Roland Bamou; Borel Djiappi-Tchamen; Albin Fontaine; Claire L Jeffries; Thomas Walker; Christophe Antonio-Nkondjio; Anthony John Cornel; Timoléon Tchuinkam Journal: Insects Date: 2020-05-15 Impact factor: 2.769
Authors: Yuri Ushijima; Haruka Abe; Georgelin Nguema Ondo; Rodrigue Bikangui; Marguerite Massinga Loembé; Vahid R Zadeh; Joseph G E Essimengane; Armel V N Mbouna; Emmanuel B Bache; Selidji T Agnandji; Bertrand Lell; Jiro Yasuda Journal: BMC Infect Dis Date: 2021-03-17 Impact factor: 3.090
Authors: Martin Wainaina; David Attuy Vey da Silva; Ian Dohoo; Anne Mayer-Scholl; Kristina Roesel; Dirk Hofreuter; Uwe Roesler; Johanna Lindahl; Bernard Bett; Sascha Al Dahouk Journal: PLoS Negl Trop Dis Date: 2022-01-24
Authors: Fredy Brice N Simo; Jean Joel Bigna; Sebastien Kenmoe; Marie S Ndangang; Elvis Temfack; Paul F Moundipa; Maurice Demanou Journal: Sci Rep Date: 2019-09-20 Impact factor: 4.379